Biotech Startups

Figura Analytics develops platform technology for the characterisation of nanomaterials, biomarkers, pharmaceuticals, and environmental pollutants. Spun out in January 2021, the company applies its analytical technology across multiple sectors.

1 investor

Filament Health develops naturally derived, botanical psychedelic compounds into pharmaceutical-grade medicines, using a development pathway aimed at reducing drug development time. The company targets both pharmaceutical and non-pharmaceutical markets for psychedelic drug products.

1 investor

FimmCyte develops targeted immunotherapies for fibro-inflammatory diseases, with a focus on conditions like endometriosis affecting women. The company aims to create disease-modifying treatments for chronic diseases impacting women's health.

1 investor

Find Therapeutics is a clinical-stage biopharmaceutical company developing therapies to treat demyelinating diseases, particularly multiple sclerosis and related conditions affecting myelin repair. The company was founded in 2020 and is based in Canada with backing from multiple life sciences investors.

1 investor

Fingerpaint Group is a life sciences marketing and agency services company offering a portfolio of specialized solutions for brands in the pharmaceutical, biotech, medical device, and animal health sectors. It serves major global pharmaceutical companies with services spanning brand development and healthcare marketing.

1 investor

Finnadvance Ltd. develops organ-on-chip platforms that recreate microphysiological conditions to accelerate drug development and research with improved cost-efficiency and reliability. The platforms serve pharmaceutical companies and research institutions by enabling faster evaluation of drug efficacy and toxicology.

1 investor

Fios Genomics provides bioinformatics data analysis services for drug discovery, development, and applied research to biotechnology and pharmaceutical companies, contract research organizations, and academic institutions. The company specializes in analyzing high-dimensional datasets and converting genomic data into actionable biological insights.

1 investor

Firefly Biotech develops technology and tools for space medicine, including microgravity tissue culture solutions built from materials chemistry and PC2 workflows, aimed at research biologists studying biology in space environments. The company also works on rapid healthcare tools and medical prototypes to support people living and working in space.

1 investor

Firefly develops neurodiagnostic technology that combines quantitative EEG (qEEG) and event-related potentials (ERP) to assess brain function, analyzing recordings against an FDA-cleared, age-matched normative database. Its tools support clinicians in evaluating cognitive disorders and enable collaboration with CNS drug developers on biomarkers, clinical trials, and companion diagnostics.

1 investor

First Ascent Biomedical provides personalized cancer treatment recommendations using a proprietary live-cell testing platform that evaluates individual tumor response to 150+ FDA-approved therapies. The company serves oncologists and cancer patients, delivering treatment insights within approximately 10 days to enable faster, more effective care decisions.

1 investor

firstocean acts as the local licence holder for pharmaceutical companies, registering and commercializing already-approved medicines (FDA/EMA-approved or Phase III assets) in secondary markets across Latin America, the Middle East, and Southeast Asia. It handles regulatory registration, pricing, pharmacovigilance, and distribution through licensed partners, taking payment only from what the medicine earns once on the market.

1 investor

Fitgenes is an Australian company that provides DNA-based genetic testing and personalised health and wellness reports covering diet, weight management, healthy ageing and lifestyle. It sells its products through a global network of over 1,000 certified independent health practitioners.

1 investor

FitnessGenes provides personalized health guidance based on DNA, blood, and wearable data to help people identify health risks early and take preventive action. The platform serves individuals seeking to extend healthy lifespan through data-driven insights grounded in genetic analysis.

1 investor

Five Alarm Bio develops pharmaceutical compounds targeting a novel aging mechanism to prevent and treat age-related chronic diseases. The company uses chemical synthesis and screening, along with cellular and animal models, to identify small molecules that restore cellular defense mechanisms against chemical damage associated with aging.

1 investor

Flagship Biosciences is a CLIA-certified, CAP-accredited spatial biology and biomarker services company that combines AI-powered tissue analysis with scientific consultation. It serves pharmaceutical and biotech companies in drug development and diagnostics.

1 investor

Flerie invests in and builds companies working on pharmaceutical and biotech projects or adjacent capabilities, using its network, expertise, and resources to support their growth. It operates as an investment firm focused on the life sciences sector.

1 investor

Fletcher Bio engineers natural immune proteins using protein design to create precision immunotherapies that target and eliminate autoreactive T cells. The company focuses on autoimmune diseases, aiming to restore immune balance for conditions with high unmet need.

1 investor

Floaxiom develops NanoSurface, a biologically manufactured affinity nanoparticle platform for antibody (mAb) purification, offering a chromatography-free alternative to protein A resin columns and membrane systems. It targets biomanufacturing process development teams with suspension-based capture (NanoFlo) integrated into tangential flow filtration and magnetic bead (NanoMag) formats.

1 investor

Flomics develops liquid biopsy tests using next-generation sequencing and machine learning to detect cancer and other complex diseases from blood samples for clinical diagnostics. The company also provides end-to-end genomics solutions including data generation, analysis, and bioinformatics support for research and clinical projects.

1 investor

FloraWorks develops rare and novel cannabinoid-based therapeutic ingredients, focusing on non-intoxicating cannabinoids validated through peer-reviewed research and toxicology testing. It targets the health, wellness, and supplement markets, aiming to bring scientifically validated cannabinoid products to mainstream retailers.

1 investor

Flourish Research operates a network of clinical trial research sites specializing in patient recruitment and retention across therapeutic areas including cardiometabolic disease, neuroscience, oncology, and infectious diseases. The company serves pharmaceutical sponsors and contract research organizations (CROs) by providing integrated site infrastructure, patient access, and standardized operations for studies across all research phases.

1 investor

flowbone develops a first-in-class injectable bioactive hydrogel that triggers the body to deposit its own minerals and form new bone, aimed at preventing osteoporotic hip fractures. It is a preclinical-stage medical technology company spun off from EPFL's Laboratory of Biomechanical Orthopedics, with products still in development.

1 investor

Yokogawa Fluence Analytics develops patented process analytics and control technologies, including its ACOMP system for real-time polymer reaction monitoring and its ARGEN static light scattering instrument for biopolymer stability testing. It serves polymer and biopharmaceutical manufacturers and researchers worldwide, and was acquired by Yokogawa Electric Corporation in January 2023.</parameter> <parameter name="founders">[]

1 investor

Fluidic Sciences develops in-solution technologies and instruments for protein interaction analysis, enabling researchers to measure how proteins interact without immobilization complexities. The company serves biomedical scientists and researchers seeking faster, more accurate understanding of molecular interactions.

1 investor